Table 5 Uni and multi-variate analysis for PFS in the cohort of patients treated with Lenvatinib.
Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
HR | 95% CI | P value | HR | 95% CI | P value | |
Sex | ||||||
Female | 1.77 | 1.17–2.68 | 0.0006 | 1.75 | 1.24–2.47 | 0.0015 |
Male | ||||||
Viral | ||||||
Y | 1.12 | 0.89–1.43 | 0.3410 | |||
N | ||||||
Nash | ||||||
N | 1.13 | 0.87–1.45 | 0.3685 | |||
Y | ||||||
Diabetes | ||||||
N | 1.12 | 0.88–1.42 | 0.3423 | |||
Y | ||||||
Metformin | ||||||
N | 1.03 | 0.76–1.39 | 0.8542 | |||
Y | ||||||
Statin | ||||||
N | 1.26 | 0.81–1.95 | 0.3536 | |||
Y | ||||||
Aspirin | ||||||
Y | 1.36 | 0.84–2.19 | 0.1605 | |||
N | ||||||
Insulin | ||||||
Y | 1.60 | 0.90–2.87 | 0.0518 | |||
N | ||||||
Child | ||||||
B | 1.95 | 1.09–3.50 | 0.0021 | 1.87 | 1.19–2.93 | 0.0068 |
A | ||||||
BCLC | ||||||
C | 1.07 | 0.84–1.35 | 0.5966 | |||
B | ||||||
Ecog | ||||||
> 0 | 1.08 | 0.82–1.43 | 0.5886 | |||
0 | ||||||
Portal vein thrombosis | ||||||
Y | 1.06 | 0.76–1.49 | 0.7159 | |||
N | ||||||
AFP | ||||||
> 400 | 1.63 | 1.22–2.18 | 0.0002 | 1.56 | 1.19–2.04 | 0.0013 |
≤ 400 | ||||||
NLR | ||||||
≥ 3 | 1.28 | 0.97–1.69 | 0.0619 | |||
< 3 | ||||||
Albumin | ||||||
≤ 3.5 | 1.43 | 1.10–1.87 | 0.0044 | |||
> 3.5 | ||||||
Bilirubin | ||||||
> 2 | 1.04 | 0.71–1.53 | 0.8226 | |||
≤ 2 | ||||||
ALT | ||||||
> 22 | 1.00 | 0.78–1.29 | 0.9873 | |||
≤ 22 | ||||||
AST | ||||||
> 56 | 1.22 | 0.92–1.16 | 0.1382 | |||
≤ 56 | ||||||
Extra hepatic disease | ||||||
Y | 1.09 | 0.85–1.38 | 0.4946 | |||
N | ||||||
HFSR | ||||||
N | 1.42 | 1.05–1.91 | 0.0219 | 0.83 | 0.62–1.11 | 0.2031 |
Y | ||||||
Hypertension | ||||||
N | 1.41 | 1.10–1.82 | 0.0122 | 0.86 | 0.67–1.10 | 0.2337 |
Y | ||||||
Fatigue | ||||||
Y | 1.04 | 0.83–1.32 | 0.7242 | |||
N | ||||||
Diarrhea | ||||||
N | 1.39 | 1.05–1.84 | 0.0386 | |||
Y | ||||||
Decrease appetite | ||||||
N | 1.02 | 0.81–1.29 | 0.8373 | |||
Y | ||||||
Proteinuria | ||||||
N | 1.00 | 0.77–1.31 | 0.9715 | |||
Y | ||||||
